Key facts
- This page summarizes Robert Weinstein's Form 4/A - Amendment filing for PharmaCyte Biotech, Inc. (PMCB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Jul 2026, 17:00.
Robert Weinstein - 31 Mar 2026 Form 4/A - Amendment Insider Report for PharmaCyte Biotech, Inc. (PMCB)
- Reporting relationship
- Director
- Issuer ticker
- PMCB
- Reported as of
- 31 Mar 2026
- Net transaction value
- $0
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 17 Jul 2026, 17:00:02 UTC
- Original report date
- 02 Apr 2026
- Prior SEC filing
- 02 Mar 2026
- Next SEC filing
- 19 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Weinstein
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
Robert Weinstein filed Form 4/A - Amendment for PharmaCyte Biotech, Inc. (PMCB) on 17 Jul 2026.
Change
- Previous filing in this sequence was filed on 02 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reporting Owners (1)
CIK 0001213709
Primary reporting owner
WEINSTEIN ROBERT
- Relationship
- Director
- Address
- C/O PHARMACYTE BIOTECH, INC., 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS
- Signature
- /s/ Robert Weinstein
- Signature date
- 17 Jul 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PMCB
transaction
Derivative
Stock Option (Right to Buy)
Other
- Transaction value
- Shares
- 0
- Change %
- Price
- Shares after
- 0
- Date
- 31 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The reported grant was made in error and has been cancelled.